Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (MDT). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Medtronic Inc Announces Initiation Of Clinical Trial Assessing Guideline-Based Heart Failure Management In Primary Care Setting
Medtronic Inc announced the initiation and first patient enrollment in a clinical study that will evaluate gaps in the implementation of evidence-based treatment guidelines among chronic heart failure patients post-hospital discharge. The IMPROVE HF Bridge Study will analyze approximately 120 patients from four different centers in the United States for a period of six months following their initial hospital stay. Patients will be cared for in the outpatient setting by either a primary care physician alone, or by both a heart failure specialist and primary care physician throughout the study.
Latest Developments for Medtronic Inc
- Medtronic Inc's In.Pact Falcon Drug-Eluting Balloon Yields Positive Outcomes in Small Coronary Arteries
- Medtronic Inc Issues FY 2014 Guidance; EPS Guidance Above Analysts' Estimates-Conference Call
- Medtronic Inc Receives 'CE' Mark for 'Export Advance' Aspiration Catheter
- Medtronic Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
- Share this
- Link this
- Digg this


Follow Reuters